Rafferty Asset Management
ERNA icon

Rafferty Asset Management’s Eterna Therapeutics ERNA Stock Holding History

Rafferty Asset Management’s Portfolio ERNA Stock Details ERNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-12
Closed -$46K – 1174
2022
Q2 		$46K Buy
12
+6
+100% +$43.1K ﹤0.01% 1107
2022
Q1 		$95K Buy
+6
New +$114K ﹤0.01% 1173

Other funds holding ERNA

LSAG
Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IC
Inverness Counsel New York $1.8B AUM 9.9% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rafferty Asset Management's ERNA Position: Q3 2022 in Review

Rafferty Asset Management sold out of Eterna Therapeutics (ERNA) in Q3 2022, closing a stake of 12 shares — an estimated $46K sold.

Rafferty Asset Management first reported a position in ERNA in Q1 2022 and held it in 2 quarters. The position peaked at $95K in Q1 2022. 31 funds tracked by Wall St. Rank hold ERNA as of Q3 2022.

  • Rafferty Asset Management reported no remaining Eterna Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Rafferty Asset Management sold 12 Eterna Therapeutics shares in Q3 2022, an estimated $46K.
  • Rafferty Asset Management first reported a position in Eterna Therapeutics in Q1 2022 and held it in 2 quarters.
  • Rafferty Asset Management's Eterna Therapeutics position peaked at $95K in Q1 2022.
  • 31 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q3 2022.

Based on Rafferty Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.